Company Overview
Korro Bio, Inc. operates as a biopharmaceutical entity dedicated to the discovery, development, and commercialization of genetic medicines that utilize RNA editing technologies to address rare and highly prevalent diseases within the United States. The company functions within the healthcare sector, specifically under the biotechnology industry, positioning itself as a developer of therapeutic solutions for complex genetic conditions rather than a standard consumer goods or service provider. Currently, the organization employs 58 individuals and holds a market capitalization of $157.49M, with annual revenue generated over the trailing twelve months totaling $6.39M. These financial figures indicate that the company is a small-cap biotechnology firm operating with a relatively lean operational structure, where the revenue base of $6.39M supports a market valuation that is significantly elevated relative to its sales output.
Financial Health
The company reported revenue of $6.39M for the trailing twelve months, yet it recorded a net income loss of $117,260,000 and an EBITDA loss of $83,062,000 during the same period. The substantial gap between the $6.39M revenue and the $117.26M net income loss reveals a cost structure dominated by high research and development expenses and operating costs that far exceed current sales revenue. The company generated free cash flow of $-49,361,752, indicating a significant cash burn rate that limits immediate financial flexibility and necessitates the utilization of existing cash reserves to fund ongoing operations and clinical trials. Three distinct margin metrics further illustrate the financial pressure: a gross margin of 0.0%, an operating margin of -1229.3%, and a profit margin of 0.0%. The negative operating margin of -1229.3% specifically highlights that operating expenses are more than twelve times the magnitude of the company's revenue, a typical characteristic of early-stage biotechnology firms but one that severely impacts profitability. In terms of liquidity and leverage, the company holds $75.16M in cash against $43.49M in debt, resulting in a debt-to-equity ratio of 84.54. While the debt-to-equity ratio of 84.54 suggests a leveraged balance sheet, the cash position provides a buffer against the debt obligations. The current ratio stands at 6.90, which indicates a robust short-term liquidity position where current assets are nearly seven times the value of current liabilities. Finally, the return on equity is -110.7% and the return on assets is -32.1%, metrics that reveal the company is currently destroying shareholder value and utilizing assets inefficiently in the context of traditional profitability measures, consistent with a pre-revenue or low-revenue biotech business model.
Valuation Assessment
Valuation metrics for Korro Bio present a complex picture due to the lack of profitability, with a trailing P/E ratio of N/A and a forward P/E of -1.44. The negative forward P/E of -1.44 implies that the market is pricing the stock based on future earnings expectations that are currently projected to remain negative, reflecting the high risk associated with the company's development stage. The price-to-book ratio is 2.00, indicating that the market values the company at twice its book value, which suggests a premium placed on the company's intellectual property and potential pipeline despite current losses. Alternative valuation multiples provide further context, with a price-to-sales ratio of 24.64 and an EV/EBITDA of -1.51. The price-to-sales ratio of 24.64 suggests that investors are willing to pay a high multiple relative to sales, driven by expectations of future commercial success rather than current cash flow generation. The stock trades within a volatile range defined by a 52-week high of $55.89 and a 52-week low of $5.20, with the current price situated significantly closer to the upper end of this historical range compared to the lower bound. The beta value is 2.54, which indicates that the stock's price volatility is more than two and a half times that of the broader market, exposing holders to substantial price swings during periods of market turbulence.
Growth & Income
The company experienced a revenue growth rate of -43.1% year over year, while earnings growth is listed as N/A due to the lack of profitable earnings to track. The negative revenue growth suggests a contraction in sales, whereas the N/A earnings growth reflects the company's status as a non-profitable entity where traditional year-over-year earnings comparisons are not applicable. As the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%. Because there are no dividend payments, the 0.0% payout ratio is mathematically consistent with the fact that the company reinvests all available resources, if any, or its cash reserves directly into research and development rather than distributing income to shareholders. The overall growth and income profile for Korro Bio is characterized by negative revenue expansion, a complete absence of dividend income, and a reliance on capital markets or cash reserves to sustain operations in the absence of positive cash flow generation.